<DOC>
	<DOCNO>NCT00737373</DOCNO>
	<brief_summary>In trial , FLOT evaluate therapy option elderly patient ( &gt; 65 year ) advance gastric cancer comparison well establish FLO scheme . The hypothesis FLOT effective FLO elderly patient acceptable side effect .</brief_summary>
	<brief_title>Oxaliplatin 5-Fluorouracil With Without Docetaxel Elderly Patients ( &gt; 65 ) With Stomach Esophagus Cancer</brief_title>
	<detailed_description>Patients locally advance , potentially operable metastatic gastric cancer adenocarcinoma esophagogastric junction without prior therapy palliative setting treat : - Arm A : FLO - Arm B : FLOT max . 12 cycle Evaluation quality life standard form baseline every 2 month progress disease . Pharmacogenetic analysis do evaluate risk profile platin-based therapy . 140 patient treat ( 70 per arm ) primary endpoint : - Response Rate secondary endpoint : - Prospective Validation pharmacogenetic risk profile patient advance GC first-line therapy platin/docetaxel - Evaluation quality life - safety tolerability - progression free survival ( PFS ) , time treatment failure ( TTF ) , overall survival ( OS )</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>metastatic locally advanced gastric cancer adenocarcinoma esophagogastric junction prior chemotherapy metastatic state adequate blood biochemistry parameter hypersensitivity 5FU , Leucovorin , Oxaliplatin Docetaxel KHK , cardiomyopathy cardiac insufficiency malignancy &lt; 5 year ago brain metastasis severe internal disease inadequate blood biochemistry parameter</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>